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Excess fatty acids accompanied by triglyceride accumulation
in parenchymal cells of multiple tissues including skeletal
and cardiac myocytes, hepatocytes, and pancreatic beta
cells results in chronic cellular dysfunction and injury.
The process, now termed lipotoxicity, can account for many
manifestations of the ‘metabolic syndrome’. Most data
suggest that the triglycerides serve primarily a storage
function with toxicity deriving mainly from long-chain
nonesterified fatty acids (NEFA) and their products such as
ceramides and diacylglycerols. In the kidney, filtered NEFA
carried on albumin can aggravate the chronic tubule damage
and inflammatory phenotype that develop during proteinuric
states and lipid loading of both glomerular and tubular cells
is a common response to renal injury that contributes to
progression of nephropathy. NEFA-induced mitochondrial
dysfunction is the primary mechanism for energetic failure
of proximal tubules during hypoxia/reoxygenation and
persistent increases of tubule cell NEFA and triglycerides
occur during acute renal failure in vivo in association with
downregulation of mitochondrial and peroxisomal enzymes
of beta oxidation. In acute renal failure models, peroxisome
proliferator-activated receptor alpha ligand treatment can
ameliorate the NEFA and triglyceride accumulation and
limits tissue injury likely via both direct tubule actions and
anti-inflammatory effects. Both acute and chronic kidney
disease are associated with systemic manifestations of the
metabolic syndrome.
Kidney International (2006) 70, 1560–1566. doi:10.1038/sj.ki.5001834;
published online 6 September 2006
KEYWORDS: lipids; proteinuria; progression of nephropathy; acute renal
failure; insulin resistance; pancreatic beta-cell
The damaging effects of cellular lipid overload are well
documented in the contribution of macrophage uptake of
oxidized low-density lipoprotein to the pathogenesis of atheros-
clerosis.1,2 Acute toxicity from accumulation of long-chain
nonesterified fatty acids (NEFA) and their metabolites
during tissue ischemia has been recognized for over 40
years.3 During the past decade it has become appreciated
that excess NEFA availability or decreased normal
oxidative metabolism, often, but not always accompanied
by triglyceride accumulation in parenchymal cells of multiple
nonadipose tissues including skeletal and cardiac myocytes,
hepatocytes, and pancreatic b-cells results in chronic
cellular dysfunction and injury in common disease states
such as insulin resistance, pancreatic b-cell dysfunction,
cardiomyopathy, and steatohepatitis. The general process
has come to be termed lipotoxicity.4,5 Its most severe
systemic expression occurs in states of clinical and experi-
mental leptin deficiency or resistance.5 However, there is
substantial evidence that lipotoxicity can account for major
manifestations of the metabolic syndrome and its complica-
tions wherein abdominal obesity and insulin resistance are
associated with a self-reinforcing cycle of dysfunctional
effects of NEFA in skeletal muscle, liver, pancreas, and
heart.4–6 Acute toxicity of NEFA and chronic lipotoxicity
contribute to acute renal failure and progression of chronic
kidney disease.
Lipotoxicity is usually accompanied by accumulation of
neutral lipids in cells as triglycerides. Most data indicate
that the triglycerides themselves serve primarily a storage
function with toxicity deriving mainly from NEFA and
their products such as ceramides and diacylglycerols that
accumulate either as a result of failure of esterification or
breakdown of the triglycerides.4,7 As summarized in Figure 1,
multiple pathways can be involved in the acute and chronic
cellular effects of NEFA excess. These vary in their
contributions from cell to cell and also for different eliciting
conditions. Some of the processes listed are well-documented
direct effects, others are indirect. This brief review will
summarize major relevant findings in nonrenal tissues that
provide insight into pathogenic mechanisms that have not
yet been studied in detail in the kidney and will provide
an overview of available information on the contribution
of lipotoxic effects in the kidney to acute and chronic renal
disease.
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SKELETAL MUSCLE CELLS, PANCREATIC b-CELLS,
HEPATOCYTES, AND CARDIAC MYOCYTES
NEFA excess contributes importantly to insulin resistance in
skeletal muscle via promotion of protein kinase C and IkB
kinase-dependent serine phosphorylation of insulin receptor
substrate-1, which blocks tyrosine phosphorylation of the
molecule, limiting activation of phosphatidylinositol-3 kinase
and AKT, and, thereby, glut4 translocation to the plasma
membrane.8 Increases of myocyte intracellular NEFA can
result from excess systemic delivery, decreased myocyte
mitochondrial density, or respiratory enzyme levels,8 or
alterations in circulating cytokines such as adiponectin9 that
regulate rates of mitochondrial b-oxidation of NEFA.
Lipotoxicity figures prominently in current concepts of
both acute and chronic pancreatic b-cell dysfunction.
Acutely, activation of the mitochondrial uncoupling protein,
ucp2, by superoxide generated during respiration driven by
either glucose or NEFA can decrease mitochondrial mem-
brane potential (DCm), adenosine triphosphate (ATP)
production, and, therefore, insulin secretion.8,10,11 High
glucose and NEFA also both up regulate ucp2 expression.10
Interestingly, only the increases of DCm and ATP production
in response to glucose are affected by the higher ucp2
expression. Baseline DCm and ATP levels are not changed.
12
The importance of mobilization of NEFA from triglycerides
rather than the triglycerides themselves in the development
of b-cell lipotoxicity is shown by the ability to elicit it by
specific transgenic overexpression in b-cells of hormone-
sensitive lipase, which increases NEFA levels, but decreases
triglyceride accumulation.13 Toxic effects of lipid overload
can also result from excess NEFA synthesis within b-cells as
shown by studies of conditional overexpression in a cultured
pancreatic b-cell line of the sterol regulatory element binding
protein (SREBP)-1c, which promotes endogenous fatty acid
synthesis.14
Thus, NEFA-associated alterations of mitochondrial
function in both tissues are proposed to play a central role
in the dysfunctional behavior of pancreatic b-cells and
skeletal myocytes that characterizes insulin resistant states.
Insufficient mitochondrial metabolism of NEFA in myocytes
suppresses the stimulation by insulin of intracellular path-
ways mediating glucose uptake, causing insulin resistance,
and hyperglycemia. High glucose and NEFA-induced activa-
tion and enhanced expression of ucp2 in mitochondria of
pancreatic b-cells suppress the increases of mitochondrial
energization and ATP production normally induced by
glucose. This limits the closing of plasma membrane ATP-
sensitive potassium channels that produces the plasma
membrane depolarization and resulting calcium influx
required for insulin release.8,11
Chronically, NEFA loading of b-cells leads to apoptosis
and decreased islet mass.5 Saturated NEFA are particularly
toxic and their toxicity is enhanced by decreasing their
oxidative metabolism.15 Initial work modeling the process in
cultured islets suggested major roles for ceramide and
inducible nitric oxide synthase in leading to apoptosis.5
Recent studies have implicated endoplasmic reticulum
stress16 and activation of calpain-10.17 Increased glucose
enhances lipotoxicity by both additive and complementary
effects on the cellular pathways of injury.15
Hyperglycemic and hyperinsulinemic states promote
hepatocyte steatosis, which is further aggravated by excess
NEFA delivery from lipolysis in visceral adipocytes. The
resulting lipotoxicity can lead to nonalcoholic steatohepati-
tits.6 The cellular pathways involved include increases of
reactive oxygen species production from oxidation of the
NEFA via the mitochondrial electron transport chain,
peroxisomal b-oxidation, and microsomal cytochrome
P450, and increased production of tumor necrosis factor-
alpha.18 There is evidence that the stimulation of tumor
necrosis factor-alpha expression is mediated by NEFA
promotion of Bax translocation to lysosomes followed by
cathepsin B release and nuclear factor-kappa B activation.19
Effects of NEFA and their coenzyme A and carnitine esters
during acute myocardial ischemia have been extensively
studied.20 Chronic myocardial cell lipotoxicity is seen in both
acquired and genetic alterations of fatty acid oxidation
pathways and with increased NEFA delivery from systemic
metabolic effects. In acquired cardiomyopathies, there is a
shift from the normal use of fatty acids as favored substrates
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Figure 1 | Cellular pathways of lipotoxicity.
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for oxidative metabolism to glucose, which results in
accumulation of NEFA and triglycerides.4,21 Clinical and
experimental settings with loss or gain of function mutations
of fatty acid-metabolizing enzymes that favor NEFA accu-
mulation in myocytes produce similar overload. The obese
fa/fa Zucker diabetic fatty rat, which has nonfunctional leptin
receptors, displays prominent increases of myocyte triglycer-
ides, ceramide, and nitric oxide synthase levels, and
myocardial contractile dysfunction.5 These animals have
severe abdominal obesity, hypertriglyceridemia, and in-
creased circulating levels of NEFA and develop multiorgan
manifestations of lipotoxicity including insulin resistance,
and hepatic as well as myocardial cell steatosis.5 As in
pancreatic b-cells, saturated NEFA such as palmitate are
maximally toxic to cardiac myocytes and limiting oxidative
NEFA metabolism promotes toxicity.21–23 Palmitate-induced
decreases of cardiolipin promote apoptosis of myocytes by
favoring mitochondrial release of cytochrome c.24
Although pancreatic b cells, skeletal, and cardiac myo-
cytes, and hepatocytes have received the most study, there is
evidence for similar lipotoxicity in both vascular smooth
muscle and endothelial cells.25 In all these cell types,
saturated NEFA display the greatest toxicity and under some
conditions unsaturated NEFA can be protective by favoring
triglyceride synthesis from the saturated NEFA.26 However,
unsaturated NEFA also have well-documented toxicity in
various settings both via direct effects such as the involve-
ment of arachidonic acid in mediating tumor necrosis factor-
alpha-induced cytotoxicity27 and as a consequence of their
metabolism.28
PROGRESSION Of CHRONIC RENAL DISEASE
In 1982, Moorhead29 proposed that lipid accumulation
contributes to chronic kidney injury. The concept that
behavior analogous to that induced by low-density lipo-
protein during atherogenesis occurs in glomerular macrophages
and mesangial cells and contributes to the progression of
glomerulosclerosis is supported by studies of effects of
modification of dietary lipids and lipid lowering drugs by
Keane et al., Diamond and coworkers, and others in the late
1980s and thereafter.2,30,31 These investigations included
studies of the progression of the focal sclerosing glomer-
ulonephritis that develops spontaneously in the Zucker
diabetic fatty rat and similar models.30,32,33
During nephrotic syndrome, circulating albumin, which
normally contains o1 NEFA/albumin molecule, becomes
saturated with 5–6 NEFA,34 increasing NEFA delivery to the
kidney and to proximal tubule cells after endocytosis of the
filtered albumin. A notable exception to this pattern is
minimal change disease, where the filtered albumin is
selectively depleted in lipids and which is not associated
with tubulointerstitial injury.35 Tubule cells become lipid
loaded during these proteinuric states (other than minimal
change disease) and the shed cells account for the oval fat
bodies that appear in the urine. Thomas and Schreiner36
originally proposed that the fatty acids bound to filtered
albumin promoted its toxicity to tubules via conversion to a
proinflammatory metabolite. Multiple NEFA effects listed in
Figure 1 could favor transformation of tubule cells to a
proinflammatory phenotype, driving progression of tubu-
lointerstitial inflammation and fibrosis. In support of this
concept, delipidated albumin is less toxic to isolated tubule
cells than untreated or fatty acid-loaded albumins37 and the
changes associated with protein overload-induced protein-
uria are ameliorated when delipidated albumin rather than
nontreated albumin is administered.38,39 Furthermore, the
toxicity of delipidated albumin is restored by allowing it to
bind NEFA.40 Promotion of tubule cell apoptosis by
albumin-bound NEFA can be mediated through activation
of peroxisome proliferator-activated receptor (PPAR)g by
the NEFA.37
A necessary role for protein reabsorption by the tubule
epithelium in the progression of tubulointerstitial damage as
opposed to events induced by glomerular leakage of protein
into the interstitium has been questioned based on morpho-
logic patterns of periglomerular injury in these states and the
development of tubulointerstitial disease during puromycin
nephritis in analbuminemic rats.41 However, the associations
between the extent and characteristics of lipiduria
in human nephrotic syndrome42 and the experimental
studies comparing nephropathy produced by low and high
lipid forms of foreign albumins.38–40 favors a pathogenic role
for NEFA delivery. Podocytes are targets for NEFA-mediated
lipotoxicity pathways that merit further investigation and
may in at least some settings be more primary targets than
the mesangial cells that have typically been studied as
glomerular sites of lipid effects.43
Lipotoxicity during progressive renal disease can also be
mediated by dysfunctional changes of intrinsic kidney cell
lipid metabolism. A series of recent studies by Levi et al. has
shown that maladaptive renal cell lipid synthesis in both the
glomerular and tubular compartments driven by injury-
induced increases of expression of SREBP isoforms is a
common feature of models of progressive renal injury
induced by Type I and Type 2 diabetes, caloric overload
and aging.44–47. Angiotensin-2 also increased expression renal
expression of SREBP-1 and lipid deposition in tubular
epithelial and vascular wall cells.48 Transgenic overexpression
of SREBP-1a induced glomerulosclerosis, tubulointerstitial
injury, and cellular lipid loading in both glomeruli and
tubules.44 Mutant mice lacking SREBP-1c were protected
against high fat diet-induced cellular lipid loading and
glomerulosclerosis.47
Although there are no data from large studies with renal
functional parameters as a primary endpoint, there is
growing evidence for efficacy of statins in limiting progres-
sion of nephropathy in clinical trials focused on cardio-
vascular endpoints.49 In contrast, results of studies using
fibrates, which modify NEFA metabolism as PPARa ligands,
are more limited and are mixed.49,50 However, it is likely that
further information will be forthcoming from continuing
investigation of PPAR agonists.51 Uremia is associated with
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a complex, secondary atherogenic dyslipidemia.52 However,
even in the absence of diabetes and with either no decrease or
only mild reduction of glomerular filtration rate, patients
followed for renal disease had increased insulin resistance and
hypertriglyceridemia compared to controls matched for age,
gender, and body mass index.53 Whether this is simply owing
to the increased diuretic use in the renal patients or indicates
aggravating systemic effects of renal dysfunction is not yet
clear, but the circulating lipid abnormalities could serve to
aggravate the renal injury.
ACUTE RENAL FAILURE
NEFA accumulate progressively during renal ischemia in vivo
and during hypoxia and metabolic inhibition of isolated
tubules in vitro via both calcium-dependent and independent
mechanisms.54 However, their importance to the outcome of
injury has remained uncertain owing to the difficulty of
separating their role from the myriad other events occurring
during ATP depletion, conflicting, or inconclusive results of
studies using phospholipase inhibitors,54 effects in some
studies of removing NEFA with delipidated albumin to
aggravate injury55–57 and, as shown by Zager et al.57, actions
of exogenous phospholipase and NEFA to protect against
plasma membrane damage during hypoxia while at the same
time impairing recovery of ATP during reoxygenation. Recent
work by Feldkamp et al.54 has demonstrated that NEFA in
fact have a primary role in determining cellular recovery of
proximal tubules during early reoxygenation via highly
reversible, direct effects to de-energize mitochondria. In
these studies, proximal tubules subjected to hypoxia/reoxy-
genation under conditions relevant to ischemia/reperfusion
in vivo developed a severe energetic deficit characterized by
persistent ATP depletion and impaired recovery of DCm
during reoxygenation that could be prevented and reversed
by supplementation with specific citric acid cycle metabolites
such as a-ketoglutarateþmalate that promote anaerobic
mitochondrial ATP production. a-ketoglutarateþmalate was
found to strikingly decrease NEFA accumulation during
hypoxia and to promote their clearance during reoxygena-
tion. Addition of NEFA to permeabilized, normoxic control
tubules in the amounts reached during hypoxia and ischemia
in vivo decreased DCm and inhibited ATP production.
Treating digitonin-permeabilized tubules at the end of
hypoxia/reoxygenation with delipidated albumin to remove
excess NEFA produced almost complete recovery of DCm and
restored ATP production. Although less potent than in
permeabilized tubules, addition of delipidated albumin to
unpermeabilized tubules during hypoxia/reoxygenation also
improved energetics and strongly added to the benefit of
a-ketoglutarateþmalate so that the two maneuvers in
combination resulted in remarkably strong recovery of
energetic function after a prolonged hypoxic insult.54 The
benefit of delipidated albumin for both the permeabilized
and unpermeabilized tubules occurred despite the availability
under both conditions of endogenous fatty acid binding
proteins,58 which indicates that the normal levels of the
endogenous proteins do not limit NEFA availability suffi-
ciently to protect mitochondrial function. In this regard, it is
of interest that Noiri et al.59 have recently reported in abstract
form that transgenic overexpression of L-type fatty acid
binding protein in mouse proximal tubules ameliorated
ischemia/reperfusion injury in vivo.
Zager et al.60,61 have shown that tubule cell accumulation
of both cholesterol and triglycerides is a continuing response
during multiple models of acute renal injury including
ischemia/reperfusion, endotoxemia, glomerulonephritis, and
ureteral obstruction. The cholesterol accumulation was
associated with cytoresistance to subsequent insults.60
Accumulation of triglycerides induced by NEFA loading, on
the other hand, was associated with sensitization to both ATP
depletion and oxidant injury.61 The simplest explanation for
triglyceride accumulation under these conditions is that
excess NEFA are diverted to triglycerides, the formation of
which is ATP-dependent.62 However, Zager’s studies have
shown that the continuing triglyceride accumulation can
involve multiple determinants of triglyceride synthesis in a
model-dependent fashion including changes of fatty acid
synthase, fatty acid transport protein, and acyl coenzyme
A:diacylglycerol transferases.62 In contrast to the results in
chronic injury models where SREBP was increased,44–48
several models of acute renal failure were associated with
early decreases of SREBP.63 Zager et al.64 has also documen-
ted persistent increases of ceramide levels after both ischemic
and nephrotoxic insults. Sphingomyelinase activity was
concomitantly decreased, so the changes of ceramide derive
from either increased synthesis as postulated for nonrenal
tissues subjected to palmitate excess5 or, less likely, decreased
catabolism.
Studies by Portilla et al.65–69 have emphasized the presence
of persisting disturbances of mitochondrial and peroxisomal
b-oxidation of fatty acids during both ischemic and cisplatin-
induced acute renal failure. These changes are driven by
downregulation of enzyme gene transcription resulting from
decreased DNA binding activity of PPARa and decreased
expression of its coactivator, peroxisome proliferator acti-
vated receptor-gamma coactivator-1, and were alleviated by
fibrates and other PPARa ligands with improvement of renal
function and prevention of necrotic and apoptotic tubule cell
death. Importantly, the PPARa ligand effects were not seen in
PPARa null mice,66 supporting specific mediation by this
pathway. The benefit of PPARa ligands during the in vivo
models was associated with anti-inflammatory effects,70
which could be secondary to decreased tubule cell production
of inflammatory mediators or systemic drug effects on
inflammatory cells. LLC-PK1 cells treated with cisplatin
develop increases of NEFA and triglycerides and decreases in
message and activity of enzymes of b-oxidation.67 PPARa
ligand treatment of LLC-PK1 cells limited cisplatin-induced
accumulation of NEFA and cisplatin-induced mitochondrial
translocation of BAX, cytochrome c, release and caspase
activation,71 confirming direct effects at the tubule cell
level. PPARa ligand treatment could theoretically worsen
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lipotoxicity by increasing fatty acid synthesis and cellular
uptake. Such effects are evident in experimental cardiomyo-
pathy,21 but over longer time frames than the benefit in the
acute kidney models is seen. Apoptotic pathways play a major
role in cisplatin-induced tubule cell injury71 and may be
promoted by the NEFA increases documented in the model.72
It is also of interest that the protective effects of PPARa
ligands in the model occur despite effects of PPARa
activation to increase expression of cyclin-dependent kinases,
which aggravate injury.73
Progressive increases of kidney tissue NEFA and triglycer-
ides occurred during cisplatin toxicity in vivo. These changes
were prominent during the first 2 days after drug, well before
cell death, and were prevented by fibrate treatment.69
Hypertriglyceridemia, hyperglycemia, and hyperinsulinemia
were also seen after cisplatin and were ameliorated by
fibrates,69 which is consistent with induction by cisplatin of
systemic lipotoxicity in addition to its tubule cell effects.
These findings are of particular interest in view of the data
that multiorgan failure states are characterized by hyper-
glycemia and insulin resistance and that intensive care unit
morbidity, including acute renal failure, and mortality can be
decreased by intensive insulin therapy.74 The association
between hyperglycemia, insulin resistance and mortality
during acute renal failure in the intensive care unit setting
has been further documented in a recently reported analysis
of the Program to Improve Care in Acute Renal Disease study
data.75 Although the precise mechanisms for these effects
remain to be defined, they raise the interesting possibility
that effects of NEFA such as those that impair intracellular
insulin signaling in muscle to cause insulin resistance8 are
expressed on additional signaling pathways involved in
cellular adaptation to stressful conditions and deleteriously
impact on cell and tissue recovery and survival during acute
renal failure.
CONCLUSION
Lipotoxicity owing to increased intracellular NEFA levels
contributes to both acute and chronic cell dysfunction
and injury in multiple tissues via several mechanisms. It
accounts for major manifestations of the metabolic syndrome
in pancreas, skeletal muscle, heart, and liver. In the kidney,
there is strong evidence that filtered NEFA carried on
albumin can aggravate the dysfunctional tubule response
seen in proteinuric states and lipid loading of both
glomerular and tubular cells also driven by increased
endogenous synthesis is a common response to renal injury
that contributes to progression of nephropathy. NEFA-
induced mitochondrial de-energization is the primary
mechanism for energetic failure of proximal tubules during
hypoxia/reoxygenation and persistent increases of tubule
cell NEFA and triglyceride levels occur during acute renal
failure in vivo in association with downregulation of
mitochondrial and peroxisomal enzymes of b-oxidation.
PPARa ligand treatment can ameliorate the NEFA and
triglyceride accumulation and limits tissue injury likely via
both direct tubule actions and anti-inflammatory effects.
Insulin resistance, which can be NEFA mediated, has been
documented during experimental cisplatin-induced nephro-
toxicity and clinical acute renal failure in the setting of
multiorgan failure and may be indicative of additional
deleterious effects of NEFA on signaling pathways involved in
recovery from injury. Continued studies of lipotoxic effects in
the kidney during acute and chronic renal disease and the
contribution of renal disease to systemic lipotoxicity are
likely to yield new insights into pathogenesis and approaches
to therapy.
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